SCHEMBL5347882

SCHEMBL5347882

CCCC(=O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@@H]1O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.63
HINT1 P49773 5/20 0.56
P2RY2 P41231 1/20 0.55
P2RY4 P51582 1/20 0.55
P2RY6 Q15077 1/20 0.55
F2 P00734 1/20 0.50
POLA1 P09884 1/20 0.49
GSK3A P49840 2/20 0.49
RPS6KA3 P51812 2/20 0.49
MAPK14 Q16539 2/20 0.49
TYMP P19971 1/20 0.47
PNP P00491 1/20 0.47
KRAS P01116 1/20 0.46
NT5E P21589 2/20 0.46
STING1 Q86WV6 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364897 0.93 POLB (0.60) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL5352210 0.93 POLB (0.60) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL5357283 0.93 POLB (0.60) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL5352650 0.93 POLB (0.60) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL9079838 0.90 HINT1 (0.53) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL8622459 0.89 POLB (0.67) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL8622463 0.89 POLB (0.67) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL367384 0.88 POLB (0.65) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL3744960 0.86 POLB (0.68) POLBHINT1P2RY2P2RY4P2RY6
SCHEMBL338650 0.86 POLB (0.70) POLBHINT1P2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307166-B1 Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-11 US disclosed
US-20040235782-A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis PRO-NEURON, INC. 2004-11-25 US disclosed
EP-1157698-A2 Treatment of inflammatory diseases with oxypurine nucleosides PRO-NEURON, INC. (US) 2001-11-28 EP disclosed
US-6060459-A Enhancing blood cell count with oxypurine nucleosides PRO-NEURON, INC. (US) 2000-05-09 US disclosed
US-6054441-A Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases PRO-NEURON, INC. (US) 2000-04-25 US disclosed
EP-0771204-A4 METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES PRO NEURON INC (US) 1999-10-20 EP disclosed
EP-0570519-B1 OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS PRO NEURON INC (US) 1999-05-06 EP disclosed
EP-0771204-A1 METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES PRO-NEURON, INC. (US) 1997-05-07 EP disclosed
WO-1996004923-A1 METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES PRO-NEURON, INC. (US) 1996-02-22 WO disclosed
EP-0570519-A4 OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS PRO NEURON INC (US) 1996-02-21 EP disclosed
EP-0570519-A1 OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS PRO-NEURON, INC. (US) 1993-11-24 EP disclosed
WO-1992013561-A1 OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS PRO-NEURON, INC. (US) 1992-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235782-A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis TPMT, NUDT1, ENTPD5 POLB 799/4885HINT1 117/4885P2RY2 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.